-
Mashup Score: 25FDA Approves T-DXd in HER2-Low/Ultralow Breast Cancer - 9 day(s) ago
Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24FDA Approves T-DXd in HER2-Low/Ultralow Breast Cancer - 22 day(s) ago
Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
OncoInfluencers to Follow on Social Media: Dr. Komal Jhaveri / Breast Cancer, cancer, Komal Jhaveri, LinkedIn, Memorial Sloan Kettering Cancer Center,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 77Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer - 3 month(s) ago
npj Breast Cancer – Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Komal Jhaveri on LinkedIn: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy… - 5 month(s) ago
Phase 1a/1b trial of Imlunestrant, brain penetrant oral SERD as monotherapy or in combination with targeted therapies in HR+ HER2 – MBC now published in JCO…
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 62
PURPOSE To investigate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of inavolisib, a potent and selective small-molecule inhibitor of p110α that promotes the degradation of mutated p110α, in combination with palbociclib and endocrine therapy (ET), in a phase I/Ib study in patients with PIK3CA-mutated, hormone receptor–positive/human epidermal growth factor receptor 2–negative locally advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT03006172). METHODS Women ≥18 years of age received inavolisib, palbociclib, and letrozole (Inavo + Palbo + Letro arm) or fulvestrant (Inavo + Palbo + Fulv arm) until unacceptable toxicity or disease progression. The primary objective was to evaluate safety or tolerability. RESULTS Fifty-three patients were included, 33 in the Inavo + Palbo + Letro arm and 20 in the Inavo + Palbo + Fulv arm. Median duration of inavolisib treatment was 15.7 and 20.8 months (cutoff: March 27, 2023), respectively. Treatm
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25New York medical school eliminates tuition after $1bn gift - 12 month(s) ago
The record-breaking donation came from a 93-year-old former professor, who is the widow of a wealthy investor.
Source: www.bbc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 70FDA approves capivasertib with fulvestrant for breast cancer - 1 year(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 1 year(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 1 year(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
T-DXd approved for HER2 low and ultralow (IHC 0 with membrane staining) breast cancer as a 1L chemotherapy option i.e. after 1 or more lines of ET in met setting #DB-06 #bcsm https://t.co/dKquEbSpnT